High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer
- 30 September 1990
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 38 (3), 386-391
- https://doi.org/10.1016/0090-8258(90)90079-z
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.Journal of Clinical Oncology, 1988
- High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's LymphomaNew England Journal of Medicine, 1987
- High-Dose Cyclophosphamide, Carmustine, and Etoposide and Autologous Bone Marrow Transplantation for Relapsed Hodgkin's DiseaseAnnals of Internal Medicine, 1986
- High dose cisplatin compared with high dose cyclophosphamide in the management of advanced epithelial ovarian cancer (FIGO stages III and IV): report from the North Thames Cooperative Group.BMJ, 1985
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- USE OF HIGH DOSE CIS-DICHLORODIAMMINE PLATINUM (II) (NSC-119875)+ FOLLOWING FAILURE ON PREVIOUS CHEMOTHERAPY FOR ADVANCED CARCINOMA OF THE OVARYBJOG: An International Journal of Obstetrics and Gynaecology, 1981
- High-dose platinum for the treatment of refractory ovarian cancerGynecologic Oncology, 1981
- Single-drug therapy in ovarian cancer: Factors influencing responseGynecologic Oncology, 1973